



European Association of Urology

GUIDELINES ON TESTICULAR CANCER*

P. Laguna, G. Pizzocaro, O. Klepp, F. Algaba,
L. Kisbenedek, O. Leiva.

TABLE OF CONTENTS	PAGE
1. Background	3
2. Classification	3
2.1 Staging	3
3. Risk factors	5
3.1 Screening	5
4. Diagnosis	5
4.1 Diagnostic tools	6
4.2 Serum tumour markers	6
4.3 Inguinal exploration and orchiectomy	7
4.4 Pathology of the testis	7
4.5 Abdominal, mediastinal and supraclavicular nodes, and state of the viscera	7
4.6 Guidelines on diagnosis and staging of testicular cancer	8
4.7 References	8
5. Treatment: stage I germ cell tumours	10
5.1 Stage I seminoma	10
5.2 Guidelines for the treatment of seminoma stage I	11
5.3 NSGCT stage I	11
5.4 CS1S with (persistently) elevated serum tumour markers	12
5.5 Guidelines on the treatment of NSGCT stage I	13
5.6 References	13
6. Treatment: metastatic germ cell tumours	17
6.1 NSGCT	17
6.2 Pure seminoma	18
6.3 Guidelines for the treatment of metastatic germ cell tumours	19
6.4 References	19
7. Follow-up: stage I non-seminoma	21
7.1 Why?	21
7.2 When and how?	21
7.3 References	22
8. Follow-up: stage I seminoma	23
8.1 Why?	23
8.2 When and how?	24
8.3 References	25
9. Follow-up: stage II and advanced metastatic disease	26
9.1 Why?	26
9.2 When and how?	26
9.3 Clinical and pathological stage II NSGCT	27
9.4 Clinical stage II seminoma	28
9.5 Clinical stage IIc and III seminoma and non-seminoma	28
9.6 References	29
10. Abbreviations used in the text	31

1. BACKGROUND

Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological tumours in general, with 3-6 new cases/occurring per 100,000 males/per year in Western society (1,2). An increase in the incidence of testicular cancer was detected during the 1970's and 1980's, particularly in Northern European countries. Only 1-2% of cases are bilateral. The histological type varies, although there is a clear predominance (90-95%) of germ cell tumours (1). Peak incidence is in the third decade of life for non-seminoma and in the fourth decade for pure seminoma. Familial clustering has been observed, particularly among siblings (3). Genetic changes have been described in patients with testicular cancer. A specific genetic marker (an isochromosome of the short arm of chromosome 12), i(12p), has been described in all histological types of germ cell tumours (3). Intratubular germ cell neoplasia (Tin) shows the same chromosomal changes, and recently alterations in the p53 locus have been found in 66% of cases of testicular Tin (4).

Currently, testicular tumours show excellent cure rates. The main factors contributing to this are: careful staging at the time of diagnosis; adequate early treatment based on chemotherapeutic combinations, with or without radiotherapy and surgery; and very strict follow-up and salvage therapies. In the last decade, a decrease in the mean time delay to diagnosis and to treatment has been observed (5).

2. CLASSIFICATION

The recommended pathological classification (modified World Health Organization) is shown below.

1. Germ cell tumours

- Intratubular germ cell neoplasia
- Seminoma (including cases with syncytiotrophoblastic cells)
- Spermatocytic seminoma (mention if there is sarcomatous component)
- Embryonal carcinoma
- Yolk sac tumour:
 - Reticular, solid and polyvesicular patterns
 - Parietal, intestinal, hepatoid and mesenchymal differentiation
- Choriocarcinoma
- Teratoma (mature, immature, with malignant component)
- Tumours with more than one histological type (specify % of individual components)

2. Sex cord stromal tumours

- Leydig cell tumour
- Sertoli cell tumour (typical, sclerosing, large cell calcifying)
- Granulosa (adult and juvenile)
- Mixed
- Unclassified

3. Mixed germ cell/sex cord stromal tumours

2.1 Staging

There are multiple staging systems, including the; tumour, node, visceral metastasis (TNM) system, the Peckham classification (Royal Marsden Hospital), the Walter Reed Hospital classification and staging systems from the European Organization for Research and Treatment of Cancer (EORTC), Memorial Sloan Kettering (MMSK) and Indiana University Hospital. It appears that each group working in the field of testicular cancer has its own staging system. The most commonly used systems are the TNM and the Peckham classification. The staging systems are generally based on the quantity of tumoural volume at diagnosis and take into account known risk factors.

The staging system recommended in these guidelines is the 1997 TNM (Table 1). This includes: determination of the anatomical extent of disease; assessment of serum tumour markers: including nadir values of beta-human chorionic gonadotrophin (beta-hCG), alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) after orchiectomy (S category); clear definition of regional nodes; and some N category modifications related to the node size (6). Nevertheless for practical purposes, treatment and follow-up (outlined in) the Peckham classification are still mentioned in this report.

According to the 1997 TNM classification, stage I testicular cancer includes the following substages:

Stage IA	pT1	N0	M0	S0
Stage IB	pT2, pT3 or pT4	N0	M0	S0
Stage IS	Any pT/TX	N0	M0	S1-3

Stage IA patients have primary tumours limited to the testis and epididymis, with no evidence of microscopic vascular or lymphatic invasion by tumour cells on microscopy, no sign of metastases on clinical examination or imaging, and post-orchietomy serum tumour marker levels within normal limits. Stage IB patients have a more locally invasive primary tumour, but no sign of metastatic disease. Stage IS patients have persistently elevated (and usually increasing) serum tumour marker levels after orchietomy, which is evidence of subclinical metastatic disease (or possibly a second germ cell tumour in the remaining testis). If serum tumour marker levels are declining according to the expected half-time decay after orchietomy, the patient is usually followed up until normalization.

In large, population-based patient series, 75-80% of seminoma patients and about 55% of patients with non-seminomatous germ cell testicular cancer (NSGCT) have stage I disease at diagnosis (7,8). True stage IS (persistently elevated or increasing serum marker levels after orchietomy) is found in about 5% of non-seminoma patients. If a staging retroperitoneal lymph nodes dissection (RPLND) is performed in stage IS patients, nearly all patients have pathological stage II disease (pN+) (1-3,8).

Table 1: The 1997 TNM staging system for testicular cancer

pT	Primary tumour				
pTx	Primary tumour cannot be assessed (if no radical orchietomy has been performed Tx is used)				
pTo	No evidence of primary tumour (e.g. histological scar in testis)				
pTis	Intratubular germ cell neoplasia (carcinoma in situ)				
pT1	Tumour limited to testis and epididymis without vascular/lymphatic invasion; tumour may invade tunica albuginea, but not tunica vaginalis				
pT2	Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis				
pT3	Tumour invades spermatic cord with or without vascular/lymphatic invasion				
pT4	Tumour invades scrotum with or without vascular/lymphatic invasion				
pN	Regional lymph nodes				
pNx	Regional lymph nodes cannot be assessed				
pN0	No regional lymph node metastasis				
pN1	Metastasis with a lymph node mass 2 cm or less in greatest dimension and five or fewer positive nodes, none more than 2 cm in greatest dimension				
pN2	Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or more than five positive nodes positive, none more than 5 cm in greatest dimension, or evidence of extranodal extension of tumour				
pN3	Metastasis with a lymph node mass more than 5 cm in greatest dimension				
pM	Distant metastasis				
The pM category corresponds to the M category					
S	Serum tumour markers				
Sx	Serum marker studies not available or not performed				
So	Serum marker study levels within normal limits				
	LDH (U/L)		Beta-hCG (mIU/ml)	AFP (ng/ml)	
S1	< 1.5 x N ^a	and	< 5,000	and	< 1,000
S2	1.5–	or	5,000–50,000	or	1.0–10.0
S3	> 10 x N	or	50,000	or	>10,000

LDH = lactate dehydrogenase; beta-hCG = beta-human chorionic gonadotrophin; AFP = alpha-fetoprotein.

^a Indicates the upper limit of normal for the LDH assay.

3. RISK FACTORS

In addition to the well-known epidemiological and clinical risk factors, a series of pathological risk factors have been identified in all staging systems, which consequently have a bearing on the prognosis. The classification of risk factors into epidemiological, clinical and pathological categories is shown in Table 2 (9-14). For clinical stage I, the most important risk factors are the histological type (seminomatous or non-seminomatous) and the presence of peri-tumoural vascular and lymphatic invasion (15). Recently, the International Germ Cell Collaborative Group (IGCCG) analysed data from 5,202 patients with NSGCT and on 660 patients with seminoma and identified some clinical independent adverse factors for metastatic disease. They devised a prognostic based staging system based on this data, in which the presence or absence of the aforementioned risk factors and the degree of elevation of serum tumour markers determined subgroups of good, intermediate or poor prognosis for NSGCT, and of good and intermediate risk for seminoma (16). The value of scrotal surgery as a risk factor remains controversial (17,18).

Table 2: Classification of risk factors for testicular cancer

<p>Epidemiological</p> <ul style="list-style-type: none">• Cryptorchidism• Klinefelter's syndrome• Familial history• Contralateral tumour• Tin• Infertility <p>Pathological (for stage I)</p> <ul style="list-style-type: none">• Histopathological type• Tumour size• Vascular/lymphatic peri-tumoural invasion <p>Clinical (for metastatic disease)</p> <ul style="list-style-type: none">• Primary location• Elevation of tumour marker levels• Presence of non-pulmonary visceral metastasis^a
--

^a Only clinical predictive factor for metastatic disease in seminoma.

3.1 Screening

Although there are no surveys proving the advantages of screening programmes, it has been demonstrated that stage and prognosis are directly related to early diagnosis.

Contralateral biopsy has been advocated to rule out the presence of Tin. Although this is routine policy in some countries, the low incidence of Tin and contralateral asynchronous testicular tumour, up to 5% and approximately 2.5% respectively, (10-13), the morbidity of Tin treatment and the fact that most of these asynchronous tumours are at a low stage at presentation precludes any recommendation (19,20).

In the presence of clinical risk factors, some self-physical examination by the affected individual is advisable.

4. DIAGNOSIS

Testicular cancer generally affects young men in the third or fourth decade of life. It normally appears as a painless, unilateral mass in the scrotum or the casual finding of an intrascrotal mass. In approximately 20% of cases the first symptom is scrotal pain and up to 27% of patients with testicular cancer have local pain (6). Occasionally, trauma to the scrotum may reveal the presence of a testicular mass. Gynaecomastia appears in 7% of cases and is more common in non-seminomatous tumours. Back and flank pain are present in about 11% of cases (5). Reduction in testis size can precede a testicular tumour (10).

In about 10% of cases, a testicular tumour can mimic an orchioepididymitis, with consequent delay of the correct diagnosis (1,2). Ultrasound must be performed in any doubtful case. Physical examination reveals the features of the mass and must always be carried out in conjunction with a general examination in order to

find possible (supraclavicular) distant metastases, a palpable abdominal mass or gynaecomastia. A correct diagnosis must be established in all patients with an intrascrotum mass (14).

4.1 Diagnostic tools

Staging represents the cornerstone on which testicular cancer treatment is based; treatment will vary according to the extent and histology of the tumour. It is mandatory to determine:

- Pre- and post-orchietomy levels of serum tumour markers
- Pathology of the testis
- Status of abdominal and supraclavicular nodes, and the liver
- Presence or absence of mediastinal nodal involvement and lung metastases
- Status of brain and bone if any suspicious symptoms are present

The recommended tests for staging at diagnosis are shown in Table 3.

Table 3: Recommended tests for staging at diagnosis

Test	Mandatory	Advisable	Optional
Tumour markers	Alpha-fetoprotein Beta-human chorionic gonadotrophin Lactate dehydrogenase		Neuro-specific enolase Placental alkaline phosphatase
Abdominal computed tomography	Young men		Slim adolescents and children
Chest X-ray	Seminoma ^a		NSGCT
Chest computed tomography	Non-seminomatous germ cell tumour		Seminoma ^a
Abdominal ultrasound	Slim adolescents and children		Young men
Testes ultrasound	Clinically suspicious and normal scrotum	Patients at risk	Abnormal testis examination
Magnetic resonance imaging			All cases
Other		If suspicious of metastatic disease	

^a If negative abdominal computed tomography (CT) scan.

4.2 Serum tumour markers

Serum tumour markers are prognostic factors and contribute to diagnosis and staging (21). The following markers should be determined:

- AFP (produced by yolk sac cells)
- Beta-hCG (β -hCG) (expression of trophoblasts)
- LDH (marker of tissue destruction)

The mean serum half-life of AFP is 5-7 days and that of beta-hCG approximately 1 day (22).

Globally, there is an increase in these markers in 51% of cases of testicular cancer (5). AFP increases in 50-70% of patients with NSGCT and a rise in beta-hCG is seen in 40-60% of patients with NSGCT. About 90% of non-seminomatous tumours present with a rise in one or two of the markers. Up to 30% of seminomas can present or develop an elevated beta-hCG level during the course of the disease (22,23). LDH is a less specific marker, and its concentration is proportional to tumour volume. Its level may be elevated in 80% of patients

with advanced testicular cancer (22). It should be noted that negative markers levels do not exclude the diagnosis of a germ cell tumour, and normalization of marker levels after treatment does not necessarily mean the absence of a tumour.

Other markers studied include neuro-specific enolase (NSE) and placental alkaline phosphatase (PLAP). NSE and/or PLAP may be of limited value in monitoring patients with pure seminoma. Cytogenetic and molecular markers are available in specific centres, but at present only contribute to research studies.

Measurement of serum AFP, beta-hCG and LDH mandatory is. NSE and PLAP are optional.

4.3 Inguinal exploration and orchiectomy

Every patient with a suspected testicular mass must undergo inguinal exploration with exteriorization of the testis within its tunics, and immediate orchiectomy with division of the spermatic cord at the internal inguinal ring has to be performed if a tumour is found.

The spermatic cord is isolated at the external ring and clamped with a soft vascular clamp. The testis is then exteriorized with its tunics. The surgical field is protected with surgical sponges, the tunica vaginalis is opened, and the testis is carefully inspected and palpated. If the diagnosis is not clear, a testicular biopsy is taken for frozen section histological examination. Once the diagnosis of testicular tumour has been established, the testis is enveloped into the sponges which protected the surgical field, gloves are changed, the inguinal channel is opened and the spermatic cord is divided at the level of the internal ring. The specimen is sent for definitive histology.

4.4 Pathology of the testis

After surgical ablation of the testis, pathological assessment is mandatory and determination of serum tumour markers is advisable.

Mandatory pathological requirements

- Macroscopic features: side, testis size, tumoural size and macroscopic features of epididymis, spermatic cord and tunica vaginalis.
- Sampling: 1 cm² section for every cm of maximal tumoural diameter, including normal macroscopic parenchyma (if present), albuginea and epididymis selection of suspected areas. At least one proximal and one distal section of spermatic cord plus any suspected area.
- Microscopic features and diagnosis: histological type (specify individual components and estimate amount as percentage). Presence or absence of peri-tumoural venous and/or lymphatic invasion. Presence or absence of albuginea, tunica vaginalis, epididymis or spermatic cord invasion. Presence or absence of intratubular germinal neoplasia in non-tumoural parenchyma.
- Category pT category according to TNM 1997.
- Immunohistochemical studies: in seminoma and mixed germ cell tumour, AFP and beta-hCG.

Advisable immunohistochemical markers

- In seminoma: cytokeratins (CAM 5.2), PLAP
- In intratubular germ cell neoplasia: PLAP
- Other advisable markers: Chromogranine A (Cg A), Ki 1, and NSE

4.5 Abdominal, mediastinal and supraclavicular nodes, and state of the viscera

Supraclavicular nodes

The supraclavicular nodes are best assessed by physical examination.

Abdominal computed tomography (CT) scan

CT scanning has clear advantages over lymphography; it offers a sensitivity of 70-80% in the determination of the state of retroperitoneal nodes. Its accuracy depends on the size of the nodes; sensitivity and negative predictive value increase using a 3-mm threshold to define metastatic nodes in the landing zones (24). Those figures decrease slightly in stages I and II (25-27), with a rate of understaging of 25-30% (28). New generations of CT scan do not seem to improve the sensitivity. An abdominal CT scan is mandatory but can be considered optional in very slim young men and children, in whom ultrasound must be performed due to lack of retroperitoneal fat.

Chest X-ray

Chest X-ray is the routine thorax examination. It is usually performed before orchiectomy in the surgical protocol. An antero-posterior and lateral chest X-ray could be considered the only thoracic examination in seminoma when retroperitoneal and pelvic CT scans are negative (29).

Chest CT scan

A chest CT scan is the most sensitive way to evaluate the thorax. This exploration has to be recommended in patients with NSGCT because up to 10% of cases can present with small subpleural nodes that are not visible radiologically (1). The CT scan has high sensitivity but low specificity (29). A chest CT is mandatory in all patients with NSGCT, and in those with seminoma and positive abdominal CT scan (29).

Ultrasound

Currently, diagnostic ultrasound serves to confirm the presence of a testicular mass and to explore the contralateral testis. Its sensitivity in detecting a testicular tumour is almost 100%, and it has an important role in determining whether a mass is intra- or extratesticular (30). Ultrasound is an inexpensive test, but it is unnecessary when the presence of a testicular tumour is clinically evident (31). Ultrasound of the testis has to be performed in young men without a palpable testicular mass who have retroperitoneal or visceral masses or elevated serum beta-hCG or AFP (32-35).

The main uses of ultrasound are as a screening test of the contralateral testis in the follow-up of patients at risk (36) and as a substitute for abdominal CT in slim young men or children.

Magnetic resonance imaging (MRI)

MRI offers higher sensitivity and specificity than ultrasound for diagnosing tumours (37-39) and may be able to differentiate seminomatous from non-seminomatous tumours. MRI of the scrotum offers a sensitivity of 100% and a specificity of 95-100% (40), but its high cost does not justify its use for diagnosis. In detection of retroperitoneal nodal enlargement, MRI produces similar results to CT scanning (41). Again, the main objections to its routine use are high cost and limited access. Nevertheless, MRI can be very helpful when abdominal CT or ultrasound are inconclusive (40) or when CT scan is contraindicated because of allergy to contrast media. MRI is an optional test and there are currently no indications for its systematic use in the staging of testicular cancer.

Other examinations

Other examinations, such as brain or spinal CT, bone scan or liver ultrasound, should be performed if there is suspicion of metastases to these organs.

4.6 GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER

1. Physical examination may be sufficient for the diagnosis of testicular cancer.
2. Testicular ultrasound is mandatory when a tumour is clinically suspected but the examination of the scrotum is normal or if there is any doubt about the clinical findings in the scrotum.
3. Pathological examination of the testis is necessary to confirm the diagnosis and define the local extension (pT category).
4. Serum determination of tumour markers (AFP, beta-hCG, LDH) must be performed before and after orchiectomy for staging and prognostic reasons.
5. Retroperitoneal, mediastinal and supraclavicular nodes and visceral state have to be assessed in testicular cancer. In seminoma, a chest CT scan is not necessary if abdominal nodes are negative.

4.7 REFERENCES

1. **Richie JP.**
Neoplasms of the testis. In: Campbell's Urology. 7th ed. Walsh PC et al. (eds). WB Saunders Co.: Philadelphia, 1997, 2411-2452.
2. **Schuttenfeld D, Warshsauer ME, Sherlock S, Zauber AG, Leder M, Payne R.**
The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980; 112: 232-246.
3. **Bosl GJ, Motzer RJ.**
Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
4. **Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, Jonas U.**
Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer 1996; 78: 1958-1966.
5. **Hermes ER, Harstad K, Fossa SD.**
Changing incidence and delay of testicular cancer in Southern Norway (1981-1992). Eur Urol 1996; 30: 349-357.
6. **Hricar H, Hamm B, Leim B.**
Imaging of the Scrotum. Textbook and Atlas. Raven Press: New York, 1995, 49-93.

7. **Zagars GK.**
Management of stage I seminoma: radiotherapy. In: Testicular Cancer: Investigation and Management. Horwich A (ed.): Chapman & Hall Medical: London, 1999, 99.
8. **Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E.**
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. *Ann Oncol* 1990; 1: 281-288.
9. **Henderson BE, Benton B, Jing J, Yu MC, Pike MC.**
Risk factors for cancer of the testis in young men. *Int J Cancer* 1979; 23: 598-602.
10. **Skakkebaek EN.**
Possible carcinoma-in-situ of the testis. *Lancet* 1972; ii: 516-517.
11. **Von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE.**
Carcinoma-in-situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. *BMJ* 1986; 293: 1398-1401.
12. **Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP.**
Intratubular germ cell neoplasia of contralateral testis in testicular cancer: defining high risk group. *J Urol* 1998; 160: 1353-1357.
13. **Giwerzman A, Bruun E, Frimotd-Muller C, Skakkebaek NE.**
Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. *J Urol* 1989; 142: 998-1002.
14. **Richie JP, Birnholz J, Gamick MB.**
Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum. *Surg Gynecol Obstet* 1982; 154: 695-698.
15. **Bokemeyer C, Schmoll HJ.**
Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. *J Cancer Res Clin Oncol* 1996; 122: 575-584.
16. **International Germ Cell Collaborative Group.**
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 1997; 15: 594-603.
17. **Pizzocaro G, Zanoni F, Salvioni R, Milani A, Piva L, Pilotti S.**
Difficulties of the surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. *J Urol* 1987; 138: 1393-1396.
18. **Bolleau M, Steers W.**
Testis tumors: the clinical significance of the contaminated scrotum. *J Urol* 1984; 132: 51-54.
19. **Herr HW, Sheinfeld J.**
Is biopsy of the contralateral testis necessary in patients with germ cell tumors? *J Urol* 1997; 158: 1331-1334.
20. **Albers P, Goll A, Bierhoff E, Schoeneich G, Muller SC.**
Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. *Urology* 1999; 54: 714-718.
21. **Klein EA.**
Tumor markers in testis cancer. *Urol Clin North Am* 1993; 20: 67-73.
22. **Peyret C.**
Tumeurs du testicule. Synthèse et recommandations en onco-urologie. *Prog Urol* 1993; 2: 60-64.
23. **Javadpour N.**
The role of biologic markers in testicular cancer. *Cancer* 1980; 45: 1755-1761.
24. **Leibovitch I, Foster RS, Kopecky KK, Donohue JP.**
Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. *J Urol* 1995; 154: 1759-1763.
25. **Jing B, Wallace S, Zornoza J.**
Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography. *Radiol Clin North Am* 1985; 20: 511-530.
26. **Husband JE, Barrett A, Peckham MJ.**
Evaluation of computed tomography in the management of testicular teratoma. *Br J Urol* 1981; 53: 179-183.
27. **Marincek B, Brutschin P, Triller J, Fuchs WA.**
Lymphography and computed tomography in staging nonseminomatous testicular cancer: limited detection of early stage metastatic disease. *Urol Radiol* 1983; 5: 243-246.
28. **Swanson DA.**
Role of retroperitoneal lymphadenectomy (RLDN) when patients with nonseminomatous germ cell testicular tumors are at high risk of needing lymph node surgery plus chemotherapy. In: *Lymph Node Surgery in Urology*. International Society of Urology Reports. Donohue JP (ed.). Isis Medical Media: Oxford, 1995, 133-140.

29. **See WA, Hoxie L.**
Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. *J Urol* 1993; 150: 874-878.
30. **Doherty FJ.**
Ultrasound of the nonacute scrotum. In: *Seminars in Ultrasound, CT and MRI*. Raymond HW et al. (eds). WB Saunders Co.: New York, 1991, 131-156.
31. **Comiter CU, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR.**
Nonpalpable intratesticular masses detected sonographically. *J Urol* 1995; 154: 1367-1369.
32. **Friedrich M, Claussen CD, Felix R.**
Immersion ultrasound of testicular pathology. *Radiology* 1981; 141: 235-237.
33. **Glazer HS, Lee JKT, Melson GL, McClennan BL.**
Sonographic detection of occult testicular neoplasm. *Am J Roentgenol* 1982; 138: 673-675.
34. **Bockrath JM, Schaeffer AJ, Kiess MS, Nieman HL.**
Ultrasound Identification of Impalpable testicle tumor. *J Urol* 1983; 130: 355-356.
35. **Shawker TH, Javadpour N, O'Leary T, Shapiro E, Krudy AG.**
Ultrasonographic detection of burned-out primary testicular germ cell tumors in clinically normal testes. *J Ultrasound Med* 1983; 2: 477-479.
36. **Lenz S, Giwercman A, Skakkebaek EN.**
Ultrasound in detection of early neoplasia of the testis. *Int J Androl* 1987; 10: 187-190.
37. **Thurnher S, Hricak H, Carroll PR, Pobielski RS, Filly RA.**
Imaging the testis. Comparison between MR imaging and US. *Radiology* 1988; 167: 631-636.
38. **Mattrey RF.**
Magnetic resonance imaging of the scrotum. *Semin Ultrasound CT MR* 1991; 12: 95-108.
39. **Rholl KS, Lee JKT, Ling D, Heiken JP, Glazer HS.**
MR imaging of the scrotum with a high resolution surface coil. *Radiology* 1987; 163: 99-103.
40. **Johnson HO, Mattrey RF, Phillipson J.**
Differentiation of seminomatous from nonseminomatous testicular tumors by MRI. *Am J Roentgenol* 1990; 154: 539-543.
41. **Ellis JH, Blies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP.**
Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. *J Comput Assist Tomogr* 1984; 8: 709-719.

5. TREATMENT: STAGE I GERM CELL TUMOURS

5.1 Stage I seminoma

After modern staging procedures, about 15-20% of stage I seminoma patients have subclinical metastatic disease, usually in the retroperitoneum, and will relapse after orchiectomy alone (1).

Prophylactic radiotherapy

Seminoma cells are extremely radiosensitive. Prophylactic radiotherapy to so-called dog-leg (DL) fields, bilaterally covering the para-aortic (PA) and the ipsilateral iliac lymph nodes, with moderate doses (24-30 Gy), will reduce the relapse rate to only 1-3%. After modern radiotherapy nearly all relapses will first occur outside the irradiated field (supradiaphragmatic lymph nodes or in the lungs) (2). Based upon the results of a large randomized Medical Research Council (MRC) trial, Fosså *et al.* (2) recommended radiotherapy to an ipsilateral para-aortic field as standard treatment for patients with testicular seminoma stage I, T1-T3 and with undisturbed lymphatic drainage. The acute toxicity was reduced and the sperm count within the first 18 months was significantly higher after unilateral para-aortic irradiation than after irradiation of the traditional dog-leg field. On the other hand, the relapse rate in the iliac lymph nodes was about 2% (all of them on the right side) after para-aortic and 0% after dog-leg irradiation. Another possible site of failure is in the left renal hilum. Para-aortic irradiation should be tailored according to the site of the primary tumour. Prophylactic irradiation of supradiaphragmatic lymph nodes is not indicated in seminoma stage I.

The rate of severe radiation-induced long-term toxicity is less than 2%. Moderate chronic gastrointestinal (GI) side-effects are seen in about 5% of patients and moderate acute GI toxicity in about 60% (2). The main concern surrounding prophylactic radiotherapy is the potentially increased risk of radiation-induced secondary non-germ-cell malignancies, including leukaemia (3-5). A total evaluation of the extra risk after prophylactic radiotherapy for stage I seminoma is difficult at present as former treatment procedures included larger fields, higher doses of radiotherapy and/or the use of alkylating chemotherapy.

Surveillance

Several prospective non-randomized studies of surveillance have been conducted during the last decade, several of which comprised more than 100 patients. The actuarial relapse rate is of the order of 15-20% at 5 years, and most of the relapses are first detected in infra-diaphragmatic lymph nodes (1,6). About 70% of the patients relapsing after surveillance are suitable for treatment with radiotherapy alone. Only about 20% of these patients relapse after salvage radiotherapy and need salvage chemotherapy. The overall cancer-specific survival rate reported by experienced centres is 98-100% for seminoma stage I after surveillance (6).

A pooled (multivariate) analysis based on the three largest studies of testicular seminoma stage I managed by surveillance indicates that a primary tumour of over 4 cm in size and invasion of the rete testis are important prognostic factors for relapse, with hazard ratios of 1.9 and 2.0, respectively (7).

The main drawback of surveillance is the need for more intensive follow-up, especially with repeated imaging examinations of the retroperitoneal lymph nodes, for at least 5 years after orchiectomy. This compares with the very low risk of subdiaphragmatic relapse after prophylactic radiotherapy. About 20% of the relapses seen after surveillance occur more than 4 years after orchiectomy (6).

Cost analyses of surveillance compared with radiotherapy indicate that it is more expensive (8), but estimates vary from extra costs of US \$4,755 to Can \$2,620 per patient (9), spread out over 10 years, or about US \$3,122 per life saved (10).

Prophylactic chemotherapy

Chemotherapy is very effective in advanced seminoma and may be an alternative to radiotherapy or surveillance in stage I seminoma (6). One or two courses of adjuvant carboplatin seem to reduce the relapse rate to the order of 1-2% (11,12), but further experience and long-term observations are needed before such adjuvant chemotherapy can be recommended as a routine option. A joint MRC and EORTC trial is comparing adjuvant radiotherapy with one course of carboplatin, but the results are not yet available (2).

RPLND

In a prospective, non-randomized study comparing radiotherapy and RPLND in stage I seminoma, there was a trend towards a higher incidence of retroperitoneal relapses (9.5%) after RPLND as primary treatment. Therefore this policy should not be recommended in stage I seminoma (11).

5.2 GUIDELINES FOR THE TREATMENT OF SEMINOMA STAGE I

1. Prophylactic radiotherapy to a para-aortic field, or a dog-leg field, to a total dose of 24-30 Gy.
2. Surveillance (available facilities).
3. Carboplatin based chemotherapy is only recommended in the setting of clinical trials

5.3 NSGCT stage I

If true stage IS cases are excluded, up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchiectomy.

RPLND

If RPLND is performed, about 30% of patients are found to have retroperitoneal lymph node metastases, pathological stage II (PS2) disease. If no retroperitoneal metastases are found (PS1) at RPLND, approximately 10% of the PS1 patients relapse at distant sites (3-10,12-16). The main predictor of relapse in CS1 NSGCT managed by surveillance, and both for having PS2 disease and for relapse in PS1 after RPLND, is histopathological evidence of vascular invasion by tumour cells near the primary tumour in the testis (13,15,17). The presence of vascular invasion seems to be a very robust parameter, and is clinically usable even without centralized review by an expert panel (15,18).

Patients without vascular invasion constitute about 70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, compared with a 50% relapse rate in patients with vascular invasion. The risk of relapse for PS1 patients is less than 10% for those without vascular invasion and about 30% for those with vascular invasion (15,18-20).

If CS1 patients with PS2 are only followed up after RPLND, about 30% relapse, mainly at sites outside the abdomen and pelvis. The risk of relapse depends upon the amount of retroperitoneal disease resected (21-23). If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in the PS2 cases, the relapse rate is reduced to less than 2%, including teratoma relapse (13,18,24).

The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (less than 2%), as is the risk of ejaculatory disturbance or other significant side-effects (16,21,22). The follow-up after RPLND is much simpler and less costly than that carried out during surveillance post-orchiectomy due to the reduced need for abdominal CT scans (16).

A laparoscopic RPLND may become a good alternative to an open RPLND, but currently it should be considered as experimental (25,26).

Surveillance

Improvements in clinical staging and follow-up methods, and the availability of effective salvage treatment with cisplatin-based chemotherapy and post-chemotherapy surgery, have led to studies of only close surveillance after orchiectomy in CS1 NSGCT patients. The largest reports of the surveillance strategy indicate a cumulative relapse rate of about 30%, with 80% of the relapses occurring during the first 12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years, and occasionally even later (17,27,28). About 45% of relapsing patients have normal levels of serum tumour markers at relapse. About 60% of the relapses are detected clinically in the retroperitoneum. Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease. Half of the deaths reported were attributable to the relapse or to salvage therapy. The somewhat lower relapse rates reported from surveillance studies compared with those expected based on patients staged by RPLND (13) can be explained by the fact that some patients (presumably at risk) are excluded once surveillance is advised.

Good patient compliance and a fail-safe infrastructure for follow-up procedures are absolute prerequisites for achieving the near 100% survival rate obtainable after RPLND. A patient offered surveillance must be made fully aware of the required intensity and duration of follow-up and the potentially fatal implications of the failure to comply.

Primary chemotherapy

Several studies involving two courses of chemotherapy with bleomycin, etoposide and cisplatin, (BEP) as primary treatment for high-risk patients (having about 50% risk of relapse) have been reported (29-33). In these series, involving more than 200 patients, some with a median follow-up of nearly 8 years (30), a relapse rate of only 2.7% was reported, with very little long-term toxicity.

It is important to be aware of the risk of slow-growing retroperitoneal teratomas after primary chemotherapy and of the risk of chemoresistant cancer relapse. The need for repeated and long-term follow-up with imaging (CT or ultrasound) of the retroperitoneum after primary chemotherapy is not yet clear.

The results of cost analyses comparing surveillance, RPLND and primary chemotherapy show different results among the reported studies, possibly because of differences in intensity and costs related to follow-up procedures. However, overall costs for the different options in treating CS1 may be of the same order of magnitude (8-10,34).

Risk-adapted treatment

As with primary chemotherapy, a policy of stratifying patients with CS1 NSGCT according to their presumed risk of relapse may be a rational option. Several studies have reported similar survival rates and a final cure rate close to 100% (18,29-32,35). The main selection criterion for high-risk patients was the presence of vascular invasion in those treated with primary chemotherapy or RPLND, and that for low-risk patients was the absence of vascular invasion following surveillance.

5.4 CS1S with (persistently) elevated serum tumour markers

Serum tumour markers should be followed closely until it is clear whether or not levels are falling according to the expected half-time values for AFP and beta-hCG. If the marker level does not fall and/or increases after orchiectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathologically documented nodes in the retroperitoneum (36). An ultrasound examination of the contralateral testicle must be performed, if this has not been done initially.

The treatment of true CS1S patients is still controversial. They may be treated with either three courses of primary BEP chemotherapy, with follow-up as for CS1B (high risk; see below) patients after primary chemotherapy (37), or by RPLND (34). The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy sooner or later anyway.

5.5 GUIDELINES FOR THE TREATMENT OF NSGCT STAGE I

CS1A (pT1, no vascular invasion); low risk

1. If the patient is willing and able to comply with a surveillance policy and long-term (at least 5 years) close follow-up is feasible, surveillance is equivalent to nerve-sparing RPLND.
2. If RPLND reveals PN+ (nodal involvement) disease, adjuvant chemotherapy with two courses of BEP should be considered.

CS1B (pT2-pT4); high risk

One of the following active treatments is recommended.

1. Nerve-sparing RPLND, which must be bilateral if PN+ disease is revealed perioperatively (nerve-sparing on the opposite side).
2. Primary chemotherapy with two courses of BEP. Until further long-term results regarding risk of retroperitoneal relapse are available, this option should be considered in the setting of clinical trials.

5.6 REFERENCES

1. **Sternberg CN.**
The management of stage I testis cancer. *Urol Clin North Am* 1998; 25: 435-449.
2. **Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP.**
Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. *J Clin Oncol* 1999; 17: 1146-1154.
3. **Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R.**
Second cancer risk following testicular cancer: a follow-up study of 1909 patients. *J Clin Oncol* 1993; 11: 415-424.
4. **Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr.**
Risk of second malignant neoplasms among long-term survivors of testicular cancer. *J Natl Cancer Inst* 1997; 89: 1429-1439.
5. **Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C.**
Mortality and cancer incidence following treatment for seminoma of the testis. *Radiother Oncol* 1994; 30: 193-198.
6. **Warde P, Jewett MAS.**
Surveillance for stage I testicular seminoma. Is it a good option? *Urol Clin North Am* 1998; 25: 425-433.
7. **Warde P, von der Maase H, Horwich A.**
Prognostic factors for relapse in stage I seminoma managed by surveillance. *Proc Am Soc Clin Oncol* 1998; 17: 312 (abstract 1188).
8. **Sharda N, Kinsella T, Ritter M.**
Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. *J Clin Oncol* 1996; 14: 2933-2939.
9. **Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M.**
Issues in the management of stage I testicular seminoma. *Int J Radiat Oncol Biol Phys* 1997; 39: S156.
10. **Francis RJ, Bowr M, Brunstrom G, Holden L, Newlands ES, Rustin GJ, Seckl MJ.**
Surveillance for stage I testicular germ cell tumours: a cost-benefit analysis. *Proc Am Soc Clin Oncol* 1999; 18: 315 (abstract 1186).
11. **Warszawski N, Schmucking M.**
Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. *Scan J Urol Nephrol* 1997; 31: 335-339.
12. **Pizzocaro G, Salvioni R, Zanoni F.**
Unilateral lymphadenectomy in intraoperative stage I nonseminomatous testis cancer. *J Urol* 1985; 134: 485-489.
13. **Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavallin-Stahl E, Fossa SD, Wahlqvist L.**
Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. *J Clin Oncol* 1990; 8: 509-518.
14. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrl R.**
Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. *J Urol* 1993; 149: 237-243.

15. **Lashley DB, Lowe BA.**
A rational approach to managing stage I nonseminomatous germ cell cancer.
Urol Clin North Am 1998; 25: 405-423.
16. **Foster RS, Roth BJ.**
Clinical stage I nonseminoma: surgery versus surveillance. *Semin Oncol* 1998; 25: 145-153.
17. **Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, Newlands ES, Williams CJ.**
Histopathology in the prediction of patients with stage I testicular teratoma treated by orchiectomy alone. *Lancet* 1987; ii: 294-298.
18. **Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E.**
Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.
Eur J Cancer 1997; 33: 1038-1044.
19. **Kratzik C, Holtl W, Albrecht W et al.**
Risk adapted management for NSGCT stage I: long-term results of a multicenter study.
J Urol 1996; 155: 547A.
20. **Ondrus D, Goncalves F, Kausitz J, Mat'oska J, Belan VI.**
The value of prognostic factors in the management of stage I nonseminomatous germ cell tumors (NSGCT). *Neoplasma* 1996; 43: 195-197.
21. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrl R.**
Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience using routine primary retroperitoneal lymph node dissection. *Eur J Cancer* 1995; 31A: 1599-1604.
22. **Richie JP, Kantoff PW.**
Is adjuvant chemotherapy necessary for patients with stage 1B testicular cancer?
J Clin Oncol 1991; 9: 1393-1398.
23. **Pizzocaro G, Monfardini S.**
No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumors of the testis. *J Urol* 1984; 131: 677-680.
24. **Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT.**
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. *N Engl J Med* 1987; 317: 1433-1438.
25. **Hulbert JC, Fraley EE.**
Laparoscopic retroperitoneal lymphadenectomy: New approach to pathological staging of clinical stage I germ cell tumors of the testis. *J Endourol* 1992; 6: 123-125.
26. **Bianci G, Beltrami P, Giusti G.**
Unilateral laparoscopic lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm. *Eur Urol* 1998; 33: 190-194.
27. **Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA.**
Medical Research Council prospective study of surveillance for stage I testicular teratoma.
J Clin Oncol 1992; 10: 1762-1768.
28. **Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC.**
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumors: 17 years' experience in a national study in New Zealand. *Br J Urol Int* 1999; 83: 76-82.
29. **Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R.**
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumours of the testis: a Medical Research Council report. *J Clin Oncol* 1996; 14: 1106-1113.
30. **Oliver RTD, Raja MA, Ong J, Gallagher CJ.**
Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. *J Urol* 1992; 148: 1453-1456.
31. **Studer UE, Fey MF, Calderoni A.**
Adjuvant chemotherapy after orchiectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. *Eur Urol* 1993; 23: 444-449.
32. **Böhlen D, Borner M, Sonntag RW, Fey MF, Studer UE.**
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. *J Urol* 1999; 161: 1148-1152.
33. **Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W.**
Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. *J Clin Oncol* 1996; 14: 441-448.

34. **Baniel J, Roth BJ, Foster RS, Donohue JP.**
Cost and risk benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. *Ann Surg Oncol* 1996; 3: 86-93.
35. **Ondrus D, Matoska J, Belan V.**
Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. *Eur Urol* 1998; 33: 562-566.
36. **Pizzocaro G, Nicolai N, Salvioni R.**
Marker positive clinical stage I non seminomatous germ cell tumors (NSGCT) of the testis: which primary therapy? *J Urol* 1996; 155 (Suppl): 328A.
37. **Davis BE, Herr HW, Fair WR, Bosl GJ.**
The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. *J Urol* 1994; 152: 111-113.

Table 4: Prognostic-based staging system for metastatic germ cell cancer (International Germ Cell Cancer Collaborative Group) [This table has been reorganized to comply with EAU style]

Good prognosis group	
Non-seminoma	
56% of cases 5-year PFS 89% 5-year survival 92%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP < 1,000 ng/ml • Beta-hCG < 5,000 mIU/L (1,000 ng/ml) • LDH < 1.5 x ULN
Seminoma	
90% of cases 5-year PFS 82% 5-year survival 86%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Any primary site • No non-pulmonary visceral metastases • Normal AFP • Any beta-hCG • Any LDH
Intermediate prognosis group	
Non-seminoma	
28% of cases 5 years PFS 75% 5-year survival 80%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP > 1,000 and < 10,000 ng/ml or • β-hCG > 5000 and < 50,000 mIU/l <li style="text-align: center;">or • LDH > 1.5 and < 10 x ULN
Seminoma	
10% of cases 5-year PFS 67% 5-year survival 72%	<i>Any of the following criteria:</i> <ul style="list-style-type: none"> • Any primary site • Non-pulmonary visceral metastases • Normal AFP • Any β-hCG • Any LDH
Poor prognosis group	
Non-seminoma	
16% of cases 5-year PFS 41% 5-year survival 48%	<i>Any of the following criteria:</i> <ul style="list-style-type: none"> • Mediastinal primary • Non-pulmonary visceral metastases • AFP > 10,000 ng/ml or • β-hCG > 50,000 mIU/L (10,000 ng/ml) <li style="text-align: center;">or • LDH > 10 x ULN
Seminoma	
No patients classified as poor prognosis	

PFS = progression-free survival; AFP = alpha-fetoprotein; β -hCG = beta-human chorionic gonadotrophin; LDH = lactate dehydrogenase.

6. TREATMENT: METASTATIC GERM CELL TUMOURS

Treatment of metastatic germ cell tumours depends on:

- Histology of the primary tumour
- Prognostic groups as they have been defined by the IGCCG based on 5,202 non-seminoma and 660 seminoma cases (Table 4).

There is a general consensus that treatment should start with initial chemotherapy in all cases except for low-volume stage II disease, which alternatively can be treated with primary bilateral RPLND for non-seminoma (eventually followed by two cycles of chemotherapy or by surveillance) or radiotherapy for pure seminoma (2,3).

6.1 NSGCT

Primary chemotherapy

The primary treatment of choice for advanced disease is four courses of BEP (PEB in the USA) combination chemotherapy (Table 5). These regimens have proven superiority to (cisplatin, vinblastine and bleomycin (PVB) (4,5). It has not yet been proved whether any of the intensified (6) or high-dose (7,8) chemotherapy schedules are therapeutically superior; only toxicity and costs have been increased.

Table 5.: British BEP and American PEB regimens (every 3 (4) weeks)

Drug	BEP	PEB
Cisplatin	20 mg/m ² , days 1–5 ^a	
Etoposide	120 mg/m ² , days 1, 3, 5	100 mg/m ² , days 1–5
Bleomycin	30 mg, days 2, 9, 16	

BEP = bleomycin, etoposide and cisplatin; PEB = cisplatin, etoposide and bleomycin.

^a Plus hydration.

In patients with a good prognosis, the objective is to maintain a cure rate of over 90% with minimal toxicity and few late side-effects. Randomized studies show that three courses of BEP are equivalent to: four courses of BEP (4); three courses of BEP plus one course of etoposide and cisplatin (EP) (9); and four courses of EP (10). Three courses of EP have been shown to be inferior to four courses of EP (4,11-13). Currently, three courses of American PEB is the primary treatment of choice for metastatic NSGCT with a good prognosis.

In intermediate and poor prognostic groups, no intensified or high-dose regimens have proved to be superior to four courses of standard BEP. The primary treatment of choice for NSGCT in males with an intermediate or poor prognosis is four courses of standard BEP, against which any other regimen has to be tested. Until the results of the Intergroup Study (four courses of standard BEP versus two standard plus two high-dose courses) are available, a retrospective matched-pair analysis (4) comparing first-line high-dose chemotherapy versus four courses of standard BEP suggests that first-line high-dose chemotherapy in patients with a poor prognosis may result in a significant prolongation of both progression-free and overall survival, and salvage (or second-line) high-dose chemotherapy for relapsing patients who initially received standard BEP does not appear to confirm the same survival advantage as initial high-dose chemotherapy.

Post-chemotherapy surgery

The following have been universally recognized:

- Surgical resection of residual masses after first-line chemotherapy is indicated in patients with normal or normalized levels of serum tumour markers.
- It is not possible to anticipate the histology of these masses by clinical means.
- Histology in different organ sites may be different. Overall, following BEP induction chemotherapy, only 10% of residual masses contain viable cancer, 50% contain mature teratoma and 40% contain necrotic-fibrotic tissue.

The key to success in the management of residual masses is complete resection, with histology being the second most important prognostic factor (14). Success rates are 50-70% disease-free survival for radically resected residual cancer, 70-90% for mature teratoma and over 90% for fibrosis-necrosis.

Adjuvant chemotherapy

Two courses of cisplatin, vinblastine and bleomycin (PVB), vinblastine, adriamycin and, bleomycin (VAB) or BEP given post-operatively following lymphadenectomy for 'radically' resected retroperitoneal metastases have been followed by nearly no relapses (15-19). Usually, two further courses of adjuvant chemotherapy are also given following resection of residual masses containing viable cancer. This adjuvant treatment has been questioned by some authors (16-20), who reported equivalent results in 60 radically resected patients with or without such treatment. Furthermore, it has been demonstrated in a co-operative retrospective study (21) that the major success factors in these patients are complete surgical resection and percentage of viable cancer in the residual mass, with the effect of adjuvant chemotherapy being borderline. Nevertheless, the results with adjuvant chemotherapy are not statistically superior to those resulting from very careful observation and deferred treatment in the case of relapse (22).

Salvage chemotherapy

Standard salvage chemotherapy consists of four courses of VP-16 (etoposide), ifosfamide and cisplatin (VIP) following PVB or velban, ifosfamide and cisplatin (VeIP) following BEP (23) (Table 6) (23). Pizzocaro *et al.* (24) suggested that modified VIP (PEI: cisplatin, etoposide, ifosfamide), may be superior to VeIP (PVI: cisplatin, vinblastine, ifosfamide) as salvage therapy in patients with intermediate or poor prognosis disease treated with first-line BEP. Many people are convinced that high-dose chemotherapy is superior to standard chemotherapy in the salvage setting. While waiting for the results of the randomized European study comparing four courses of salvage standard chemotherapy with three courses of standard chemotherapy plus one course of high-dose chemotherapy, Rodenhuis *et al.* (25) carried out a non-randomized prospective study of salvage high-dose chemotherapy in 34 patients. They reported 2-year event-free and overall survival rates of 51% and 65%, respectively. This compares with the 42% and 47% reported by Pizzocaro *et al.* (26) with standard PEI/PVI followed by surgery whenever possible in 76 patients, with a median follow-up of 4 years (minimum follow-up 30 months).

Recently, taxol and gemcitabine have proved to be active in the treatment of refractory germ cell tumours; both drugs are synergistic with cisplatin (27).

Table 6: Standard VIP (VeIP) versus modified PEI (PVI) salvage chemotherapy (every 3 (4) weeks)

Drug	VIP (VeIP)	PEI (PVI)
Cisplatin	20 mg/m ² , days 1-5 ^a	33.3 mg/m ² , days 3-5 ^b
Etoposide (vinblastine)	75 mg/m ² , days 1-5 (0.11 mg/kg, days 1, 2)	100 mg/m ² , days 3-5 (6 mg/m ² , day 3)
Ifosfamide ^c	1.2 g/m ² , days 1-5	2.5 g/m ² , days 1, 2

VIP = VP-16 (vinblastine) ifosfamide and cisplatin; VeIP = velban, ifosfamide and cisplatin; PEI = cisplatin, etoposide and ifosfamide; PVI = cisplatin, vinblastine and ifosfamide.

^a Plus hydration.

^b Plus double-volume hydration .

^c Plus mesna protection.

Salvage surgery

Salvage surgery is indicated whenever possible for masses residual to salvage chemotherapy and for resectable NSGCT at any site which proves to be refractory to chemotherapy. Such surgery is also performed if levels of serum tumour markers are elevated. Overall, the result of surgery is 15-20% long-term disease-free survival, with acceptable morbidity and only occasional mortality (28).

6.2 Pure seminoma

According to the IGCCG (1), no seminoma has a poor prognosis, but experience teaches that the occasional 'bad seminoma' behaves as a very malignant disease, which relapses following every kind of therapy and is inevitably fatal. It is impossible to recognize initially. Furthermore, pure seminoma is potentially curable by radiotherapy. So far, small-volume retroperitoneal metastases can be cured in over 90% of cases with a retroperitoneal moderate dose (36-40 Gy) of retroperitoneal radiotherapy alone, and most patients who relapse can be salvaged with chemotherapy. One problem is that patients pretreated with radiotherapy have a reduced

bone marrow reserve and the dosage of myelosuppressive agents has to be slightly reduced.

Advanced seminoma is also usually highly responsive to chemotherapy, and many authors suggest specific therapeutic regimens for this disease (29,30). Nevertheless, there is no reason not to use the same management as that used for the corresponding prognostic groups of NSGCT (31). The only difference is that there are often residual masses after induction chemotherapy; they contain residual cancer in only 10% of cases and are necrotic-fibrotic in the other 90%. As a rule, there is no residual teratoma in the 'true' seminoma patient. Many authors suggest resecting residual masses over 3 cm in diameter (32), but post-chemotherapy surgery in pure seminoma is usually very difficult and dangerous because of intense fibrosis (33). A good option is to treat only residual masses that do not shrink within 6 months of completion of induction chemotherapy with radiotherapy.

6.3 GUIDELINES FOR THE TREATMENT OF METASTATIC GERM CELL TUMOURS

1. Low volume NSGCT stage II can be treated either by RPLND (plus surveillance or two cycles of chemotherapy) or by primary chemotherapy.
2. In metastatic NSGCT with a good prognosis, three courses of BEP is the primary treatment of choice.
3. In metastatic NSGCT with an intermediate or poor prognosis, the primary treatment of choice is four courses of standard BEP.
4. Surgical resection of residual masses after chemotherapy in NSGCT is indicated when serum levels of tumour markers are normal or normalizing.
5. Metastatic seminoma with less than N3M1 disease can be treated initially with radiotherapy. When necessary, chemotherapy can be used as a salvage treatment with the same schedule as for the corresponding prognostic groups of NSGCT.
6. Advanced seminoma (N3 or M1) should be treated with primary chemotherapy according to the same principles used for NSGCT, but with radiotherapy for (persistent) residual masses instead of surgery.

6.4 REFERENCES

1. **International Germ Cell Collaborative Group.**
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 1997; 15: 594-603.
2. **Frohlich MW, Small EJ.**
Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. *Urol Clin North Am* 1998; 25: 451-459.
3. **Baniel J, Donohue JP.**
Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumors. *AUA Update Series* 1997; 26: 50-55.
4. **Saxman S, Finch D, Gonin R, Einhorn LH.**
Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University Experience. *J Clin Oncol* 1998; 16: 702-706.
5. **de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L.**
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. *J Clin Oncol* 1997; 15: 1837-1843.
6. **Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.**
Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. *J Clin Oncol* 1997; 15: 1844-1852.
7. **Einhorn LH, William SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA.**
Evaluation of optimal duration of chemotherapy in favorable-prognostic disseminated germ cell tumors: a SouthEastern Cancer Study Group protocol. *J Clin Oncol* 1989; 7: 387-391.
8. **Fossa SD, Saeter G, Aas N, Ous S, Stenwig AE, Blomlie V.**
Management of patients with poor-prognosis nonseminomatous germ cell cancer. *Oncology* 1990; 47: 234-240.
9. **De Wit R, Roberts JT, Wilkinson P et al.**
Is 3 BEP equivalent to 3 BEP-1EP in good prognosis germ cell cancer? An EORTC/MRC Phase III study. *Proc ASCO* 1999; 18: 309a (abstract 1187).

10. **Culine S, Kerbrat R, Bouzy J *et al.***
Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients (pts) with good risk metastatic nonseminomatous germ cell tumors (NSGCT)? Preliminary results of a randomized trial. Proc ASCO 1999; 18: 309a (abstract 1188).
11. **Bajorin DF, Geller NL, Weisen SF, Bosl GJ.**
Two-drug therapy in patients with metastatic germ cell tumors. Cancer 1991; 67: 28-32.
12. **Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ.**
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997; 15: 2553-2558.
13. **Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C.**
First-line high-dose chemotherapy (HD-CT) versus standard-dose PEB/PEI (SD-CT) in patients (pts) with advanced germ cell tumors (GCT). A matched pair analysis. Proc ASCO 1999; 18: 309a (abstract 1189).
14. **Hendry WF, Barrett A, McElwain TJ, Wallace DM, Peckham MJ.**
The role of surgery in the combined management of metastases from malignant teratomas of the testis. Br J Urol 1988; 2: 38-44.
15. **Einhorn LH, Williams SD, Mandelbaum I, Donohue JP.**
Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-908.
16. **Fox EP, Weathers TS, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH.**
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 1993; 11: 1294-1299.
17. **Gerl A, Clemm C, Schemeller N, Dienemann H, Lamerz R, Kriegmair M, Wilmanns W.**
Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumors. Ann Oncol 1995; 6: 483-488.
18. **Hollender A, Stenwig EA, Ous S, Fossa SD.**
Survival of patients with viable malignant non-seminomatous germ cell tumor persistent after cisplatin-based induction chemotherapy. Eur Urol 1997; 31: 141-147.
19. **Bajorin DF, Herr H, Motzer RJ, Bosl G.**
Current perspectives on the role of adjuvant surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992; 19: 148-158.
20. **Pizzocaro G, Nicolai N, Milani A *et al.***
Is further chemotherapy necessary in radically resected residual cancer in non-seminomatous germ cell tumors (NSGCT) of the testis following induction chemotherapy? Proc ASCO 1998; 17: 309a (abstract 1191).
21. **Fizazi K, Tjulandin S, Salvioni R *et al.***
Viable malignant cells after primary chemotherapy for metastatic non-seminomatous germ-cell tumors (NSGCT): results from an international study. Proc ASCO 1999; 18: 308A (abstract 1183).
22. **Debono DJ, Heilman DK, Einhorn LH, Donohue JP.**
Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997; 15: 1455-1464.
23. **Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH.**
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-2504.
24. **Pizzocaro G, Salvioni R, Piva L, Faustini M, Nicolai N, Gianni L.**
Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors: long-term results. Ann Oncol 1992; 3: 211-216.
25. **Rodenhuis S, de Wit R, de Mulder PHM, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EG.**
A prospective multi-center trial on repeated high dose chemotherapy in relapsing germ cell cancer. Proc ASCO 1999; 18: 310A (abstract 1190).
26. **Pizzocaro G.**
Germ Cell Tumours IV. John Libbey & Co. Ltd: London, 1998, 355-360.
27. **Reinhorn LH, Rajhavan D, Kindlen H *et al.***
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory advanced germ cell tumors. Proc ASCO 1999; 18: 207A (abstract 796).
28. **Foster FS, Donohue JP.**
Can retroperitoneal lymphadenectomy be omitted in some patients in chemotherapy? Urol Clin North Am 1999; 25: 479.

29. **Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O.**
The treatment of advanced metastatic seminoma: experience in 55 cases. *J Clin Oncol* 1987; 5: 1071-1077.
30. **Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH.**
Chemotherapy of metastatic seminoma: the SouthEastern Cancer Study Group Experience. *J Clin Oncol* 1997; 15: 1212-1220.
31. **Schultz SM, Einhorn LH, Conces DJ Jr, Williams SD, Loehrer PJ.**
Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University Experience. *J Clin Oncol* 1989; 7: 1497-1503.
32. **Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M.**
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. *J Clin Oncol* 1987; 5: 1064-1070.
33. **Friedman EL, Garnick MB, Stomper PC, Mauch PM, Harrington DP, Richie JP.**
Therapeutic guidelines and results in advanced seminoma. *J Clin Oncol* 1985; 3: 1325-1332.

7. FOLLOW-UP: STAGE I NON-SEMINOMA

7.1 Why?

Approximately 5% of patients with clinical stage I NSGCT present with elevated levels of tumour markers after orchiectomy and up to 25-30% relapse during the first 2 years (1-9). The aim of follow-up is two-fold: to detect relapse and the rare possibility of asynchronous contralateral carcinoma of the testis in an early phase, and to avoid unnecessary treatment.

7.2 When and how?

The follow-up schedule will differ depending on which of the three possible treatment strategies was chosen: surveillance, nerve-sparing retroperitoneal lymphadenectomy (RLND) or primary chemotherapy.

Follow-up after surveillance

The results of a surveillance policy depend upon a careful pre-operative staging procedure and follow-up management. Half of the relapses will occur in the first 6 months; however, recurrent disease has been detected as late as 6 years after orchiectomy. In a 'wait and see' policy, relapses will occur in 30% of cases. Of these relapses, 80% will occur in the first 12 months after orchiectomy and approximately 12% during the second year. The median time to relapse is 6 months (range 1-62 months), but relapses after 3-5 years and even later may still occur, with an annual rate of 4% (10,11). Relapse occurs mainly in the retroperitoneum; approximately 20% of patients have evident metastases in the retroperitoneum and 10% in the mediastinum and lungs (12). Sometimes the only indication is an elevated level of tumour markers.

Careful observation during the first 6 months after orchiectomy is mandatory; thereafter, the interval may be longer. Surveillance should continue for a minimum of 6 years and indefinite yearly follow-up is

Table 7: Recommended follow-up schedule in a surveillance policy: – stage I non-seminoma

Procedure	Year			
	1	2	3-5	6-10
Physical examination	Six times (monthly for the first 6 months ^a)	Four times (six times ^a)	Twice/year	Once/year ^a
Tumour markers	Six times (monthly for the first 6 months ^a)	Four times (six times ^a)	Twice/year	Once/year ^a
Chest X-ray	Six times (monthly for the first 6 months ^a)	Four times (six times ^a)	Twice/year	Once/year ^a
Abdominal computed tomography scan	Three times (four times ^a)	Twice (three times ^b)	Once/year	If indicated

^a = Advisable, ^b = Optional.

advocated by some. There is no universally accepted protocol for surveillance. A recommended follow-up schedule is shown in Table 7. It is particularly difficult to establish recommendations for those patients with negative pre-operative tumour markers levels. If RLND is not performed, patients may require closer follow-up. Currently, not enough data are available in the literature from which to derive strict recommendations.

Follow-up after nerve-sparing RLND

Retroperitoneal relapse after a properly performed nerve-sparing RLND is extremely rare. RLND should eliminate the retroperitoneal nodes as a site of relapse, and thus the need for repeated abdominal CT scans. The USA Intergroup data show retroperitoneal relapse in 7/264 patients with pathological stage I disease (and 20 pulmonary relapses); four of these seven had no marker elevation (13). In the Indiana series, only one relapse in 559 cases was reported (14). If a relapse occurs, it is generally in the chest, neck or at the margins of the surgical field. Pulmonary relapses occur in 10-12% of patients and more than 90% of those relapses occur within 2 years of RLND (15,16). The recommended follow-up schedule is shown in Table 8.

Follow-up after adjuvant chemotherapy

Although the number of patients treated using adjuvant chemotherapy is still small, some prospective reports with long-term follow-up show a very low relapse rate (1-3,17) of about 3%. The need for repeated and long-term assessment of the retroperitoneum is still not clear. Primary chemotherapy in the treatment of NSGCT cannot be regarded as investigational, but still has to be offered in the setting of clinical trials. The follow-up schedule will depend on the results of these studies, but will probably be similar to that recommended for RPLND (Table 8). Owing to the risk of developing a late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy, an abdominal CT or at least ultrasound examination should also be performed (at least) annually during the third to fifth year.

It should be noted that these recommendations represent the minimum standard of follow-up. Any other tests (e.g. hormonal determinations, spermograms, neurological examinations) or more frequent schedules of evaluation may be performed on the basis of clinical protocol or investigative purposes.

Table 8: Recommended follow-up schedule after retroperitoneal lymphadenectomy or adjuvant chemotherapy - stage I non-seminoma

Procedure	Year			
	1	2	3-5	5-10
Physical examination	Six times	Three times	Twice/year	Once/year ^a
Tumour markers	Six times	Three times	Twice/year	Once/year ^a
Chest X-ray	Six times	Three times	Twice/year	Once/year ^a
Abdominal computed tomography scan	Twice	Once	If indicated ^b	If indicated
Abdominal ultrasound	Twice ^{ac}	Twice ^{ac}	Twice/year	Once/year

^a = Advisable.

^b Due to a risk of late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy.

^c Alternating with abdominal CT scan.

7.3 REFERENCES

- Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R.**
Short-course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council Report. *J Clin Oncol* 1996; 14: 1106-1113.
- Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W.**
Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. *J Clin Oncol* 1996; 14: 441-448.

3. **Böhlen D, Borner M, Sonntag RW, Fey MF, Studer UE.**
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. *J Urol* 1999; 161: 1148-1152.
4. **Lashley DB, Lowe BA.**
A rational approach to managing stage I nonseminomatous germ cell cancer. *Urol Clin North Am* 1998; 25: 405-423.
5. **Bosl GJ, Motzel RJ.**
Testicular germ-cell cancer. *N Engl J Med* 1997; 337: 242-253.
6. **Tjan-Heijnen VCG, Oosterhof GON, de Wit R, de Mulder PHM.**
Treatment of germ cell tumours: state of the art. *Eur J Surg Oncol* 1997; 23: 110-122.
7. **Baniel J, Donahue JP.**
Cost and risk benefit considerations in low stage (I and II) non seminomatous testicular tumor. *AUA Update Series* 1997; 16 (lesson 7): 49-56.
8. **Lowe BA.**
Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I germ cell tumors. *Urol Clin North Am* 1993; 20: 75-83.
9. **Sternberg CN.**
Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. *Urol Clin North Am* 1993; 20: 93-109.
10. **Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA.**
Medical Research Council prospective study of surveillance for stage I testicular teratoma. *J Clin Oncol* 1992; 10: 1762-1768.
11. **Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC.**
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumors: 17 years' experience in a national study in New Zealand. *Br J Urol Int*, 1999; 83: 76-82.
12. **Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schraffordt Koops H.**
Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. *J Clin Oncol* 1995; 13: 1188-1194.
13. **McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP**
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. *J Urol* 1991; 145: 1178-1183.
14. **Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrlle R.**
Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University Experience 1965-1989. *Br J Urol* 1993; 71: 326-335.
15. **Schmoll HJ, Weissbach L.**
Diagnostik und Therapie von Hodentumoren, Interdisziplinäre Konsensus-Konferenz, Halle (Saale), 1996.
16. **Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E.**
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. *Ann Oncol* 1990; 1: 281-288.
17. **Oliver RTD, Raja M-A, Ong J, Gallagher CJ.**
Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. *J Urol* 1992; 148: 1453-1456.

8. FOLLOW-UP: STAGE I SEMINOMA

8.1 Why?

The majority of patients with seminoma (70-80%) present with clinical stage I disease at diagnosis (1). In 15-20% of cases, there is nodal radiological involvement at the level of the retroperitoneum and 5% of patients present with distant metastasis (1). The relapse rate varies between 1% and 20%, depending on the post-orchietomy therapy chosen. Only up to 30% of seminomas present with elevation of beta-hCG at diagnosis or in the course of the disease. Consequently, in most cases, measurement of blood markers will not be an unreliable test for follow-up (2). The aim of follow-up is to detect early recurrence and contralateral testiculars tumours and to avoid unnecessary treatment.

The treatment options post-orchietomy in stage I seminoma are retroperitoneal radiotherapy, surveillance and adjuvant chemotherapy. Due to extreme radio- and chemosensitivity, high cure rates of almost

100% are reached with each of the approaches, even in case of relapse.

The costs of the different therapies vary, as do the expected side-effects (3-5). Of major importance is the identification of potential prognostic factors, both clinical and pathological, for occult metastasis and consequent relapse.

Risk factors for relapse

Although there is no total agreement among different groups, the size of the tumour seems to be the most important risk factor for relapse in uni- and multivariate analyses. Vascular and lymphatic invasion has also proved to be an important risk factor in univariate analysis. Other risk factors are age and histological subtype (anaplastic), and local tumoural extension (6-8).

8.2 When and how?

The optimal schedule of follow-up has yet to be defined and will differ according to the treatment chosen. Different tests have to be performed according to the relapse time and pattern of relapse.

Follow-up after radiotherapy

Low doses of radiotherapy (25-26 Gy) limited to the retroperitoneal field achieve an overall survival rate of approximately 99% at 5-10 years (9,10). The rate of relapse is 1- 2% and the most common time of presentation is within 18 months after treatment (4,11,12), although late relapses have also been described (13). The site of relapse is mainly at the supradiaphragmatic lymph nodes, mediastinum, lungs or bones. In a small proportion of cases, the tumour will relapse in the inguinal or external iliac nodes (1).

The side-effects of radiotherapy include impaired spermatogenesis, gastrointestinal symptoms (peptic ulceration) and induction of second malignancies (4,14,15). Up to 50% of patients can develop moderate toxicity Grade I-II (9). The schedule of follow-up is described in Table 9.

Table 9: Follow-up for post-orchietomy radiotherapy – stage I seminoma

Procedure	Year			
	1	2	3	4-5
Physical examination	Four times	Three times	Three times	Twice/year
Chest X-ray	Four times	Three times	Three times	Twice/year
Tumour markers	Four times	Three times	Three times	Twice/year
Abdominal computed tomography scan	Once	Once	If indicated	If indicated
Abdominal ultrasound	Once ^a	Once ^a	Once	If indicated

^a Alternating with abdominal computed tomography scan.

Follow-up after surveillance

The main goal of the surveillance policy is to avoid unnecessary therapy. It must be recognized that there is a somewhat higher need for salvage chemotherapy if prophylactic radiotherapy is omitted. Alternatively, at least 80% of patients will receive unnecessary radiotherapy if this is given prophylactically to all those with seminoma stage I. There are already prospective, but not randomized, studies of surveillance showing that the actuarial risk of relapse at 5 years ranges between 15% and 20% (6,8,16-18). Nevertheless, there is no increased risk of death. The median time to relapse ranges from 12-18 months, but up to 29% of relapses can develop later (1). The sites of relapse are the PA lymph nodes in up to 82% of cases; the pelvic lymph nodes, inguinal nodes and lungs can also be affected (1). Due to the high and often late rate of relapse, close and active follow-up is mandatory for at least 5 years. The major disadvantages of this policy are lack of long-term follow-up data, high cost and patient compliance. The schedule of follow-up is described in Table 10.

Follow-up after adjuvant chemotherapy

One or two courses of carboplatin-based chemotherapy is an effective alternative treatment in stage I seminoma. The relapse rate is less than 2%, but the number of patients treated in a prospective setting is still

low and the length of follow-up is also low in most studies. In general this treatment is well tolerated, with only mild, acute and intermediate-term toxicity (19,20). As the relapse rate is low, the follow-up schedule could be the same as that proposed for post-orchietomy radiotherapy. However, until prospective study results are available, it is strongly recommended that these patients are followed up as described in the surveillance policy (Table 10).

Table 10: Follow-up for surveillance policy and adjuvant chemotherapy for seminoma stage I

Procedure	Year				
	1	2	3	4-5	6-10
Physical examination	Six times	Four times	Three times	Twice/year	Once/year
Tumour markers	Six times	Four times	Three times	Twice/year	Once/year
Chest X-ray	Six times	Four times	Three times	Twice/year	Once/year
Abdominal computed tomography scan	Four times	Four times	Twice	Once/year	If indicated
Abdominal ultrasound	^a	^a	Twice ^b	Once/year ^b	If indicated

^a Not required.

^b Alternating with abdominal computed tomography scan.

8.3 REFERENCES

- Warde P, Jewett MA.**
Surveillance for stage I testicular seminoma. Is it a good option? *Urol Clin North Am* 1998; 25: 425-433.
- McCaffrey JA, Bajorin DF, Motzer RJ.**
Risk assessment for metastatic testis cancer. *Urol Clin North Am* 1998; 25: 389-395.
- Buchholz TA, Walden TL, Prestidge BR.**
Cost-effectiveness of post-treatment surveillance after radiation therapy for early stage seminoma. *Cancer* 1998; 82: 1126-1133.
- Tana S, Cerrotta A, Gardani G, Palazzi M, Pizzocaro G.**
Post surgical policy in stage I testicular seminoma: cost and benefit of prophylactic irradiation in a long-term experience. *Tumori* 1997; 83: 918-921.
- Sharda NN, Kinsella TJ, Ritter MA.**
Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. *J Clin Oncol* 1996; 14: 2933-2939.
- Von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rorth M, Schultz H.**
Surveillance following orchidectomy for stage I seminoma of the testis. *Eur J Cancer* 1993; 14: 1931-1934.
- Warde P, Gospodarowicz M, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JF, Moore M, Jewett MA.**
Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. *J Urol* 1997; 157: 1705-1709.
- Horwich A, Alsanjari N, A'Hern, Nicholls J, Dearnaley DP, Fisher C.**
Surveillance following orchidectomy for stage I testicular seminoma. *Br J Cancer* 1992; 65: 775-778.
- Sultanem K, Souhami L, Benk V, Bahary JP, Roman T, Shenouda G, Freeman C.**
Para-aortic irradiation only appears to be adequate treatment for patients with stage I seminoma of the testis. *Int J Radiat Oncol Biol Phys* 1998; 40: 455-459.
- Kiricuta IC, Sauer J, Bohndorf W.**
Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchietomy paraaortic radiotherapy. *Int J Radiat Oncol Biol Phys* 1996; 35: 293-298.
- Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA.**
Stage I testicular seminoma: results of adjuvant irradiation and surveillance. *J Clin Oncol* 1995; 13: 2255-2262.

12. **Fossa SD, Aass N, Kaalhus O.**
Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. *Int J Radiat Oncol Biol Phys* 1989; 16: 383-388.
13. **Baniel J, Foster RS, Einhorn LH, Donohue JP.**
Late relapse of clinical stage I testicular cancer. *J Urol* 1995; 154: 1370-1372.
14. **Stein ME, Levi M, Drumea K, Moshkovitz B, Nativ O, Milstein D, Sabo E, Kuten A.**
Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968-1993). *J Surg Oncol* 1998; 67: 38-40.
15. **Akimoto T, Takahashi I, Takahashi M, Yamakawa M, Hayakawa K, Mitsunashi N, Niibe H.**
Long-term outcome of postorchietomy radiation therapy for stage I and II testicular seminoma. *Anticancer Res* 1997; 17: 3781-3785.
16. **Germá Lluch JR, Climent MA, Villavicencio H, Gomez de Segura G, Blanco R, Mercedes A, de Andres L, Sole Balcells FJ.**
Treatment of stage I testicular tumors. *Br J Urol* 1993; 71: 473-477.
17. **Warde P, Gospodarowicz MK, Goodman PJ, Sturgeon JF, Jewett MA, Catton CN, Richmond H, Thomas GM, Duncan W, Munro AJ.**
Results of a policy of surveillance in stage I testicular seminoma. *Int J Radiat Oncol Biol Phys* 1993; 27: 11-15.
18. **Allhoff EP, Liedke S, de Riese W, Stief C, Schneider B.**
Stage I seminoma of the testis: adjuvant radiotherapy or surveillance? *Br J Urol* 1991; 68: 190-194.
19. **Krege S, Kalund G, Otto T, Goepel M, Rubben H.**
Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. *Eur Urol* 1997; 31: 405-407.
20. **Dieckmann KP, Krain J, Kuster J, Bruggeboes B.**
Adjuvant carboplatin treatment for seminoma clinical stage I. *J Cancer Res Clin Oncol* 1996; 122: 63-66.

9. FOLLOW-UP: STAGE II AND ADVANCED (METASTATIC) DISEASE

9.1 Why?

The more advanced the nodal stage of the disease, the higher the likelihood of recurrence (1). In general, the primary tumour bulk governs the outcome for patients with NSGCT (2). In stage II NSGCT, regardless of the treatment policy adopted, excellent survival rates of 97% are reached provided that relapse is identified as soon as possible (3-5).

In advanced metastatic germ cell tumours, the extent of the disease is correlated with the response to therapy and with survival. The combination of cisplatin-based chemotherapy and surgery (aggressive multimodality) achieves cure rates between 65% and 85%, depending on the initial extent of disease (2,6). Complete response rates to chemotherapy are in the order of 50-60% (2); another 20-30% of patients could be rendered disease free with post-chemotherapy surgery (7).

The main reasons for failure of therapy in advanced NSGCT are (2,8,9):

- The presence of bulky disease not responding completely to chemotherapy
- Unresectable residual teratoma after chemotherapy
- Presence or development of chemoresistant non-germ elements, which account for 8.2% of cases

9.2 When and how?

The rate and timing of relapse will determine the intensity of the follow-up schedule. The pattern of relapse dictates the most appropriate tests to be performed during follow-up. There is a lack of randomized trial results from which to plan evidence-based follow-up, and the different schedules used by various centres have a higher variability and are more individualized than for stage I.

As for less advanced states, the methods of follow-up are:

- Physical examination, including the search for neck and abdominal masses, for gynaecomastia, examination of groins, superficial nodes and the remaining testis
- Tumour markers: AFP, beta-hCG and LDH
- Chest X-ray
- Abdominal and pelvic CT or abdominal ultrasound
- Chest CT
- Brain CT (in case of neurological symptoms)

9.3 Clinical and pathological stage II NSGCT

Relapse after primary RPLND

Two different situations can occur:

1. About 23-28% of clinical stage II patients will have pathological stage I disease and should be followed up accordingly (see follow-up for NSGCT stage I) (10,11).
2. Between 72% and 77% of clinical stage II patients will be of pathological stage II, having a different relapse rate depending on the type of treatment. Whatever the treatment policy chosen, the majority of relapses occur within the first 2 years and outside the surgical field.

Relapse after RPLND followed by two immediate cycles of chemotherapy:

The relapse rate for this group is 6% at 4 years (1,6). In non-randomized series, with a mean follow-up ranging from 30-72 months, this treatment policy results in a high overall disease-free survival rate of 98-100% (3,12). The main disadvantage of adjuvant chemotherapy is that it represents an overtreatment in approximately 50% of patients with stage II disease.

Relapse after RPLND followed by surveillance:

The average relapse rate in this group is 35% (range 8-49%) at a mean of 4 years (1). Nevertheless, the relapse rate depends on pathological stage; pathological stage IIa presents a risk of relapse of less than 50%, while pathological stage IIb presents a risk of relapse of at least 50% (1,3,6,13).

Following primary RPLND the retroperitoneal CT scan can be replaced by less expensive abdominal ultrasound, although a baseline post-RPLND CT scan is recommended (Table 11). When primary RPLND is followed by surveillance (generally in cases of low-volume lymph node involvement or pathological stage IIa), a stricter schedule of follow-up is needed than with adjuvant chemotherapy. A physical examination, tumour marker assessment and chest X-ray are performed more frequently than in the former treatment policy. The follow-up outlined in Table 11 can be used, but the following tests have to be performed:

- Monthly during the first year
- Bimonthly during the second year
- Three-monthly during the third year
- Every 4 months during the fourth year
- Twice in the fifth year
- Yearly thereafter

B. Relapse after primary chemotherapy

Between 68% and 78% of patients (average 75%) will reach a clinical complete response (5,14,15). The relapse rate is then around 5%, and most relapses occur in the first 8 months after chemotherapy, continuing up to 2 years. Nevertheless, later relapses in the range 2-5% may occur depending on several prognostic factors (e.g. whether the metastasis is: > 3 cm or < 3 cm in size, histology of the primary tumour/teratoid elements). Mature teratomas have been described at 5-8 years of follow-up (3). Generally, the relapse rate at a median follow-up of 5.5 years is approximately 8%. The progression-free survival rate is approximately 92% and the overall survival rate is 97% (5).

Although this treatment policy avoids RPLND in 68-78% of patients, depending on whether the clinical stage is IIa or IIb (5,14,16), it requires extended follow-up. After primary chemotherapy, retroperitoneal CT scans cannot be omitted from the follow-up schedule. The follow-up schedule is basically the same as that for primary RPLND plus adjuvant chemotherapy, although after primary chemotherapy an abdominal and pelvic CT scan has to be performed at least twice during the first 2 years (Table 11).

Table 11: Follow-up of NSGCT stage IIa–IIb after RPLND plus chemotherapy or primary chemotherapy

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Tumour markers	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Chest X-ray	Bimonthly	Four times	Twice	Twice	Twice	Once/year
Abdominal CT ^{ab}	Baseline, then as indicated	As indicated	If indicated	If indicated	If indicated	If indicated
Abdominal ultrasound	Twice	Twice	If indicated	If indicated	If indicated	If indicated

RPLND = retroperitoneal lymph node dissection; NSGCT = non-seminomatous germ cell tumour; CT = computed tomography.

^a After RPLND, a baseline CT scan of the abdomen and pelvis is obtained, and repeated if clinically indicated thereafter.

^b After primary chemotherapy, the retroperitoneum has to be monitored by means of CT scan at least twice during the first 2 years.

9.4 Clinical stage II seminoma

Relapse rates following radiotherapy for clinical stages IIa and IIb are in the range 5-15%. Most relapses occur within the first 2 years and present with a supraclavicular or mediastinal mass, while relapses in the irradiated field are rare (6).

During follow-up, attention must be paid to the specific sites of relapse (Table 12).

Table 12: Follow-up of seminoma stage IIa–IIb after radiotherapy

Procedure	Year					
	1	2	3	4	5	> 5
Physical examination	Six times	Four times	Three times	Twice	Twice	Once/year
Tumour markers	Six times	Four times	Three times	Twice	Twice	Once/year
Chest X-ray	Six times	Four times	Three times	Twice	Twice	Once/year
CT abdomen and pelvis ^a	If indicated	If indicated	If indicated	If indicated	If indicated	If indicated
CT chest ^b	If indicated	If indicated	If indicated	If indicated	If indicated	If indicated

CT = computed tomography.

^a Baseline CT of the abdomen/pelvis post-treatment and repeated only if indicated.

^b Only if there is an abnormal chest X-ray or if clinical symptoms indicate.

9.5 Clinical stage IIc and III seminoma and non-seminoma

In advanced disease following the IGCCG classification, the overall survival rate is in the order of 92% for patients in the good prognostic category, 80% for those in the intermediate category and 48% for those in the poor prognostic category (17). Stage IIc is generally grouped in the subset of patients with good prognosis (3).

After chemotherapy, careful follow-up observation is recommended if there is a decrease of at least 90% in the volume of retroperitoneal masses, provided there was no evidence of teratomatous elements in the primary tumour. Nevertheless, to date there are no reliable CT scan criteria to distinguish tumour or teratoma

from necrotic debris in the post-chemotherapy setting; false-negative CT scan rates range from 8-37% (8).

In advanced NSGCT, despite statistical correlation with a variety of factors (e.g. degree of shrinkage, size of residual mass, pre-chemotherapy tumour marker levels, teratomatous components in orchiectomy specimen), the risk of a false-negative prediction based on a CT scan is still currently approximately 20% (8). In advanced seminoma, the rate of 'in-site' failure is 3% when the CT scan is normal or shows a residual abnormality less than 3 cm in diameter (18-21).

The follow-up schedule for advanced disease (seminoma and non-seminoma) is presented in Table 13. brain CT has to be performed during follow-up if neurological symptoms are present, because up to 5% of patients with advanced disease present with or develop brain metastases (6). An abdominal CT scan has to be performed at least annually, because of the ominous significance of teratoma, if found in the retroperitoneum.

Table 13: Follow-up of advanced NSGCT and seminoma

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Tumour markers	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Chest X-ray	Monthly	Bimonthly	Four times	Three times	Twice	Once/year
Abdominal CT ^{ab}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Chest CT ^{bc}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Brain CT ^d	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated

CT = computed tomography.

^a Abdominal CT scan has to be performed at least annually if teratoma is found in retroperitoneum.

^b If the post-chemotherapy evaluation shows any mass > 3 cm, the appropriate CT scan should be repeated 2 and 4 months later to ensure that the mass is continuing to regress.

^c Chest CT is indicated if abnormality is detected on chest X-ray and after pulmonary resection.

^d In patients with headaches, focal neurological findings or any CNS symptom.

9.6 REFERENCES

- Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT.**
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. *N Engl J Med* 1987; 317: 1433-1438.
- Bukowski RM.**
Management of advanced and extragonadal germ-cell tumors. *Urol Clin North Am* 1993; 20: 153-160.
- Frohlich MW, Small EJ.**
Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. *Urol Clin North Am* 1998; 25: 451-459.
- Baniel J, Donohue JP.**
Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumors. *AUA Update Series* 1997; 7: 50-55.
- Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP.**
Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. *J Urol* 1994; 151: 72-77.
- Fair W, Dalbagni G, Machele Donat S, Theodorescu D.**
Evaluation and follow-up of patients with urologic cancer. *AUA Office of Education Publications* 9958 PG, 1999.
- Pizzocaro G.**
Non-seminomatous germ-cell tumors (NSGCT) of the testis: diagnosis and management, stage by stage. *European Urology Update Series* 1997; 6: 139-145.

8. **Sheinfeld J, Bajorin DF, Solomon M.**
Management of postchemotherapy residual masses in advanced germ cell tumors.
Urol Clin North Am 1997; 3: 18-23.
9. **Little JS, Foster RS, Ulbright TM, Donohue JP.**
Unusual neoplasms detected in testis cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy. J Urol 1994; 152: 1144-1149.
10. **Aas N, Kaasa S, Lund E, Kaalhus O, Heier MS, Fossa SD.**
Long-term somatic side-effects and morbidity in testicular cancer patients.
Br J Cancer 1990; 61: 151-155.
11. **Donohue JP, Thornhill JA, Foster RS, Bihrlé R, Rowland RG, Einhorn LH.**
The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). J Urol 1995; 153: 85-89.
12. **Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, Lyn P, Vlamis V.**
Etoposide and cisplatin adjuvant therapy for patients with pathological stage II germ cell tumors.
J Clin Oncol 1995; 13: 2700-2704.
13. **Hartlapp JH, Weissbach L, Bussar-Maatz R.**
Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 1987; 10: 277-284.
14. **Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML.**
Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 1987; 5: 906-911.
15. **Sternberg CN.**
Role of primary chemotherapy in stage I and low volume stage II nonseminomatous germ-cell testis tumors. Urol Clin North Am 1993; 20: 93-109.
16. **Foster RS, Donohue JP.**
Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?
Urol Clin North Am 1998; 25: 479-484.
17. **International Germ Cell Collaborative Group.**
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
18. **Peckham MJ, Howick A, Hendry WF.**
Advanced seminoma treatment with cisplatin based combination chemotherapy or carboplatin.
Br J Cancer 1985; 52: 7-13.
19. **Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O.**
The treatment of advanced metastatic seminoma, experience in 55 cases.
J Clin Oncol 1987; 5: 1071-1077.
20. **Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH.**
Chemotherapy of metastatic seminoma: the SouthEastern Cancer Study Group experience.
J Clin Oncol 1997; 15: 1212-1220.
21. **Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M.**
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5: 1064-1070.

* These EAU Guidelines on Testicular Cancer are endorsed by all members of the EAU Oncological Urology Group (Chairman: C. Abbou). Members of the Oncological Urology Group are the EAU Working parties on: Bladder Cancer, Renal Cancer, Penile Cancer, Prostate Cancer & Testis Cancer.

10. ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations.

AFP:	alpha-fetoprotein
BEP:	bleomycin, etoposide and cisplatin
beta-hCG:	beta-human chorionic gonadotrophin
CgA:	Chromogranine A
CT:	Computed tomography
EP:	etoposide and cisplatin
EORTC:	European Organization for Research and Treatment of Cancer
IGCCG:	International Germ Cell Collaborative Group
LDH:	lactate dehydrogenase
MMSK:	Memorial Sloan Kettering
MRC:	Medical Research Council
MRI:	Magnetic resonance imaging
NSE:	neuro-specific enolase
NSGCT:	non-seminomatous germ cell tumour
PEB:	cisplatin, etoposide and bleomycin
PEI:	cisplatin, etoposide, ifosfamide
PVI:	cisplatin, vinblastine, ifosfamide
PLAP:	placental alkaline phosphatase
PVB:	cisplatin, vinblastine and bleomycin
RPLND:	retroperitoneal lymph node dissection
Tin:	intratubular germ cell neoplasia
TNM:	Tumour Node Metastasis
VAB:	vinblastine, adriamycin and bleomycin
VelP:	velvan, ifosfamide and cisplatin

